Tags

Type your tag names separated by a space and hit enter

Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole.
Clin Exp Rheumatol 2009 May-Jun; 27(3 Suppl 54):15-21CE

Abstract

OBJECTIVE

The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD.

METHODS

The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day).

RESULTS

Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9+/-9.7 before treatment, 8.3+/-8.1 after 4 weeks of treatment, and 7.0+/-7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period.

CONCLUSION

Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs.

Authors+Show Affiliations

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ymuro@med.nagoya-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19796556

Citation

Muro, Y, et al. "Scoring of Reflux Symptoms Associated With Scleroderma and the Usefulness of Rabeprazole." Clinical and Experimental Rheumatology, vol. 27, no. 3 Suppl 54, 2009, pp. 15-21.
Muro Y, Sugiura K, Nitta Y, et al. Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. Clin Exp Rheumatol. 2009;27(3 Suppl 54):15-21.
Muro, Y., Sugiura, K., Nitta, Y., Mitsuma, T., Hoshino, K., Usuda, T., ... Matsuo, H. (2009). Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. Clinical and Experimental Rheumatology, 27(3 Suppl 54), pp. 15-21.
Muro Y, et al. Scoring of Reflux Symptoms Associated With Scleroderma and the Usefulness of Rabeprazole. Clin Exp Rheumatol. 2009;27(3 Suppl 54):15-21. PubMed PMID: 19796556.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. AU - Muro,Y, AU - Sugiura,K, AU - Nitta,Y, AU - Mitsuma,T, AU - Hoshino,K, AU - Usuda,T, AU - Hayashi,K, AU - Murase,Y, AU - Shimizu,M, AU - Matsuo,H, PY - 2009/10/3/entrez PY - 2009/12/4/pubmed PY - 2010/1/6/medline SP - 15 EP - 21 JF - Clinical and experimental rheumatology JO - Clin. Exp. Rheumatol. VL - 27 IS - 3 Suppl 54 N2 - OBJECTIVE: The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD. METHODS: The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day). RESULTS: Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9+/-9.7 before treatment, 8.3+/-8.1 after 4 weeks of treatment, and 7.0+/-7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period. CONCLUSION: Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs. SN - 0392-856X UR - https://www.unboundmedicine.com/medline/citation/19796556/Scoring_of_reflux_symptoms_associated_with_scleroderma_and_the_usefulness_of_rabeprazole_ L2 - http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=19796556 DB - PRIME DP - Unbound Medicine ER -